TY - JOUR
T1 - Pamidronate disodium and possible ocular adverse drug reactions
AU - Macarol, V.
AU - Fraunfelder, F. T.
N1 - Funding Information:
From Ciba-Geigy Limited, Basel, Switzerland (Dr. Macarol); and the Casey Eye Institute, Oregon Health Sciences University, Portland, Oregon (Dr. Fraunfelder). This study was supported, in part, by a grant from Research to Prevent Blindness, New York, New York.
PY - 1994
Y1 - 1994
N2 - Ciba-Geigy Central Epidemiology and Drug Safety Center has received 23 reports of suspected ocular adverse drug reactions associated with the use of intravenous pamidronate disodium, an inhibitor of bone resorption that is used primarily in the management of tumor-induced hypercalcemia and Paget's disease of the bone. Anterior uveitis, bilateral in six of seven patients, occurred within 24 to 48 hours after the drug was administered. The anterior uveitis recurred in four of the five patients who were rechallenged. Three reports involved unilateral episcleritis or scleritis occurring within one to six days after the administration of the drug. Only the episcleritis patient was rechallenged five months later, when the patient again had the episcleritis occur in the same eye. Thirteen patients reported nonspecific transitory conjunctivitis within six to 48 hours after pamidronate disodium was given intravenously. This was positive on rechallenge in six of eight patients. These data indicate that, on rare occasions, pamidronate disodium is a probable cause of anterior uveitis or nonspecific transitory conjunctivitis and is a possible cause of episcleritis or scleritis.
AB - Ciba-Geigy Central Epidemiology and Drug Safety Center has received 23 reports of suspected ocular adverse drug reactions associated with the use of intravenous pamidronate disodium, an inhibitor of bone resorption that is used primarily in the management of tumor-induced hypercalcemia and Paget's disease of the bone. Anterior uveitis, bilateral in six of seven patients, occurred within 24 to 48 hours after the drug was administered. The anterior uveitis recurred in four of the five patients who were rechallenged. Three reports involved unilateral episcleritis or scleritis occurring within one to six days after the administration of the drug. Only the episcleritis patient was rechallenged five months later, when the patient again had the episcleritis occur in the same eye. Thirteen patients reported nonspecific transitory conjunctivitis within six to 48 hours after pamidronate disodium was given intravenously. This was positive on rechallenge in six of eight patients. These data indicate that, on rare occasions, pamidronate disodium is a probable cause of anterior uveitis or nonspecific transitory conjunctivitis and is a possible cause of episcleritis or scleritis.
UR - http://www.scopus.com/inward/record.url?scp=0027964579&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027964579&partnerID=8YFLogxK
U2 - 10.1016/S0002-9394(14)72902-2
DO - 10.1016/S0002-9394(14)72902-2
M3 - Article
C2 - 8053468
AN - SCOPUS:0027964579
SN - 0002-9394
VL - 118
SP - 220
EP - 224
JO - American journal of ophthalmology
JF - American journal of ophthalmology
IS - 2
ER -